Navarro Alonso, Jose Antonio
Bont, Louis J.
Bozzola, Elena
Herting, Egbert
Lega, Federico
Mader, Silke
Nunes, Marta C.
Ramilo, Octavio
Valiotis, George
Olivier, Catherine Weil
Yates, Ann
Faust, Saul N. http://orcid.org/0000-0003-3410-7642
Article History
Received: 1 September 2021
Accepted: 11 October 2021
First Online: 21 October 2021
Declarations
:
: Not applicable.
: Not applicable.
: An honorarium was paid to SNFs institution for his participation in the expert group but SNF received no personal payments of any kind. SNF has acted as clinical trial investigator on behalf of his hospital for GSK, Janssen (J&J), Regeneron and Medimmune (AstraZeneca) in the field of RSV vaccines and monoclonal antibodies but SNF received no personal payment of any kind. LJB has regular interaction with pharmaceutical and other industrial partners. He has not received personal fees or other personal benefits. University Medical Centre Utrecht (UMCU) has received major funding (> €1,00,000 per industrial partner) for investigator initiated studies from AbbVie, MedImmune, Janssen, the Bill and Melinda Gates Foundation, Nutricia (Danone) and MeMed Diagnostics. UMCU has received major cash or in kind funding as part of the public private partnership Innovative Medicines Initiative-funded Respiratory Syncytial Virus Consortium in Europe project from GSK, Novavax, Janssen, AstraZeneca, Pfizer and Sanofi. UMCU has received major funding by Julius Clinical for participating in the International Network for Optimal Resistance Monitoring of RSV study sponsored by MedImmune. UMCU has received minor funding for participation in trials by Regeneron and Janssen from 2015 to 2017 (total annual estimate < €20,000). UMCU received minor funding for consultation and invited lectures by AbbVie, MedImmune, Ablynx, Bavaria Nordic, MabXience, Novavax, Pfizer and Janssen (total annual estimate < €20,000). LJB is the founding chairman of the ReSViNET Foundation. SM reports a sponsorship agreement between SP and EFCNI.